FDA Accepts Supplement Application for BESREMI (Ropeginterferon Alfa-2b-NJFT)
The FDA has accepted the supplemental application for BESREMI, a treatment involving Ropeginterferon Alfa-2b-NJFT.
Therapeutic Area
Therapeutic area intelligence for Rare Blood Disorders with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.